

# Effectiveness of nirsevimab against respiratory syncytial virus-related hospitalization in Madeira, Portugal: 2023-24

## Efetividade do nirsevimab na hospitalização por infeção a vírus sincicial respiratório na Madeira, Portugal: 2023-24

Andreia Afonso<sup>1\*</sup>, Fátima Côrte Pestana<sup>1</sup>, Mariana Rodrigues<sup>2</sup>, Alexandra Andrade<sup>1</sup>, José Alves<sup>3</sup>, Teresa Jacinto<sup>4</sup>, Edite Costa<sup>4</sup>, Bruna R. Gouveia<sup>5, 6, 7</sup>, Bernardo Camacho<sup>1</sup>, Cristina Freitas<sup>1</sup>

<sup>1</sup>Department of Pediatrics, Hospital Central do Funchal; <sup>2</sup>Investigation Centre Dr.ª Maria Isabel Mendonça, Hospital Central do Funchal; <sup>3</sup>Department of Clinical Pathology, Hospital Central do Funchal; <sup>4</sup>Department of Pediatric and Neonatal Intensive Medicine, Hospital Central do Funchal; <sup>5</sup>Regional Health Directorate, Government of the Autonomous Region of Madeira; <sup>6</sup>Interactive Technologies Institute (ITI-LARSyS); <sup>7</sup>Saint Joseph of Cluny Higher School of Nursing (ESESJCluny). Funchal, Portugal

### Abstract

**Introduction and Objectives:** Respiratory syncytial virus (RSV) is a leading cause of hospitalizations for acute lower respiratory tract infection (LRTI) in infants. Madeira was the first Portuguese region to recommend immunoprophylaxis with nirsevimab, an anti-RSV monoclonal antibody, for all infants in their first RSV season. The immunization campaign, which ran from November 2023 to March 2024, targeted infants born during the campaign (seasonal group), and those born between April and October of 2023 (catch-up group). This study aimed to assess the effectiveness of nirsevimab in preventing RSV-related LRTI hospitalizations. **Methods:** A population-based longitudinal observational study was conducted. Follow-up lasted until 150 days post-immunization, the end campaign (for non-recipients), hospitalization or death. The effectiveness of nirsevimab effectiveness was estimated using a Cox proportional hazards model adjusted for age and sex. The number needed to immunize (NNI) was calculated from absolute risk reduction. Averted cases were estimated using historical data, excluding the period of the COVID-19 pandemic. **Results:** The overall immunization rate was 97.4% (1,710/1,756), and the result was similar in the seasonal (97.7%, 728/745) and catch-up (97.1%, 982/1,011) groups. There were 0.4% (6/1,710) RSV-related LRTI hospitalizations among nirsevimab recipients versus 4.3% (2/46) among non-recipients, with an estimated effectiveness of 94.6% (95% CI 72.6-98.9). The NNI was 25. Supplemental oxygen therapy duration decreased significantly compared to previous seasons ( $P = .039$ ). The number of averted cases was 45 (IQR 15-83), with a 79.6% reduction in hospitalizations (IQR 62.6-90.9). **Conclusion:** Nirsevimab was effective in reducing hospitalizations for RSV-related LRTI in a real-world setting, offering useful evidence for future RSV immunization strategies.

**Keywords:** Respiratory syncytial virus. Monoclonal antibodies. Respiratory tract infections. Hospitalization.

### \*Correspondence:

Andreia Afonso  
E-mail: andreiaafonso14@gmail.com

Received: 08-04-2025

Accepted: 11-12-2025

<https://pjp.spp.pt>

Available online: 10-03-2025

Port J Pediatr. (Ahead of print)

DOI: 10.24875/PJP.25000024

2184-3333 / © 2025 Portuguese Society of Pediatrics. Published by Permayer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Resumo

**Introdução e Objetivos:** O vírus sincicial respiratório (VSR) é uma causa importante de infecção respiratória aguda baixa (IRAB) em lactentes. A Madeira foi a primeira região portuguesa a recomendar imunoprofilaxia com nirsevimab, um anticorpo monoclonal anti-VSR, para lactentes na sua primeira época VSR. A campanha de imunização, de novembro de 2023 a março de 2024, incluiu lactentes nascidos na época epidémica (grupo sazonal) e entre abril e outubro de 2023 (grupo *catch-up*). Este estudo teve por objetivo avaliar a efetividade do nirsevimab contra hospitalizações por IRAB a VSR. **Métodos:** Realizou-se um estudo observacional longitudinal de base populacional. O *follow-up* durou até 150 dias após a imunização, final da campanha (não imunizados), hospitalização ou morte. A efetividade foi estimada utilizando um modelo de Cox ajustado. O número necessário para imunizar (NNI) foi calculado a partir da redução do risco absoluto. O número de casos evitados foi estimado utilizando dados de épocas anteriores, excluindo o período pandémico (COVID-19). **Resultados:** A taxa global de imunização foi 97,4% (1710/1756), semelhante no grupo sazonal (97,7%, 728/745) e *catch-up* (97,1%, 982/1011). Registaram-se hospitalizações em 0,4% (6/1710) dos imunizados e 4,3% (2/46) dos não imunizados, com uma efetividade estimada de 94,6% (IC 95% 72,6-98,9). O NNI foi 25. A duração de oxigenoterapia suplementar foi significativamente menor comparando com épocas anteriores ( $P = .039$ ). O número de casos evitados foi 45 (IQR 15-83), com uma redução de hospitalizações de 79,6% (IQR 62,6-90,9). **Conclusão:** O nirsevimab foi efetivo na redução das hospitalizações por IRAB a VSR num contexto de mundo real, oferecendo evidência para futuras estratégias preventivas.

**Palavras-chave:** Vírus sincicial respiratório. Anticorpos monoclonais. Infecções do trato respiratório. Hospitalização.

### Key points

#### What is known?

- Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections requiring hospitalization in children worldwide.
- Nirsevimab has recently been approved as a preventive strategy against RSV infection, for all infants.

#### What is added?

- Madeira was the first region in Portugal to implement an immunization campaign with nirsevimab for all infants in their first RSV season in the 2023-24 RSV season.
- Our study estimated an effectiveness of 94.6% against RSV hospitalizations, with a 79.6% reduction in hospitalizations.

## Introduction


Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection (LRTI) in infants worldwide. In 2019, it was estimated that there were 3.6 million RSV-associated LRTI hospital admissions globally in children under five years of age<sup>1</sup>. RSV-related hospitalizations occur most frequently in infants under two years of age<sup>2</sup> and the risk of hospitalization decreases with increasing age<sup>3,4</sup>.

In Portugal, the annual cost of RSV-related LRTI hospitalizations was estimated at 2.4 million euros between 2015 and 2018. The highest costs were incurred by children under two years old (96%) and by previously healthy children (87.6%)<sup>2</sup>. The Madeira Archipelago, an autonomous region of Portugal situated in the North Atlantic Ocean, has approximately 256,000 inhabitants and recorded 1,747 births in 2023<sup>5</sup>. The Portuguese Network for RSV Surveillance (VigiRSV) recorded 782 cases of acute respiratory infections in children in Madeira in the 2022-23 RSV season, 65.2% of which were confirmed to be

RSV-related by real-time reverse transcription-polymerase chain reaction (RT-PCR)<sup>6</sup>.

Nirsevimab (Beyfortus®, AstraZeneca/Sanofi Pasteur) was approved by the European Medicines Agency in October 2022<sup>7</sup>. Nirsevimab is a recombinant human IgG<sub>1</sub> kappa long-acting monoclonal antibody that inhibits RSV activity by blocking viral entry into host cells<sup>8</sup> and has been proven effective and safe in preventing RSV infections in infants during their first epidemic season with a single dose injection<sup>9-12</sup>.

In October 2023, Madeira became the first region nationwide to recommend the universal use of nirsevimab as a prophylactic measure against RSV, free of charge<sup>13</sup>. The immunization campaign began on November 1<sup>st</sup>, 2023, and ended on March 31<sup>st</sup>, 2024. Those eligible for its administration included all infants in their first RSV season residing in Madeira providing protection levels for up to 150 days<sup>10-12,14,15</sup>. The campaign was aimed to immunize two groups: a seasonal group (infants born during the campaign) and a catch-up group (infants born from April 1<sup>st</sup> to October 31<sup>st</sup>, 2023). Additionally, infants with selected risk factors for severe infection were immunized.



**Figure 1.** Flowchart of infants eligible for immunization with nirsevimab. \*Maternal immunization with Abrysvo®

Infants in the seasonal group were offered a dose of nirsevimab in the maternity ward within the first days of life. Infants in the catch-up group were immunized in the primary care setting at a scheduled appointment. The administration was intramuscular, and the dose varied according to body weight (50 mg if the infant's body weight was below 5 kg, and 100 mg if it was above or equal to 5 kg)<sup>13</sup>.

The present study aimed to assess the effectiveness of nirsevimab in preventing hospitalizations for RSV-related LRTI in the 2023-24 season.

## Methods

### Study design and participants

A population-based, longitudinal, observational study was conducted. Out of all the infants born between April 1<sup>st</sup>, 2023, and March 31<sup>st</sup>, 2024, infants who died before the campaign began, who were not residing in Madeira, or whose pregnant mother was immunized with Abrysvo® were excluded (Fig. 1). All infants who were eligible for immunization with nirsevimab in the 2023-24 RSV season were included.

The infants were divided into the same groups as those defined during the immunization campaign,

according to date of birth: a seasonal group (infants born during the campaign) and a catch-up group (infants born between April 1<sup>st</sup> and October 31<sup>st</sup>, 2023).

In both groups, infants were considered nirsevimab non-recipients if there was parental refusal; if they presented respiratory symptoms compatible with RSV infection shortly before or after the scheduled administration; or if nirsevimab was administered after hospitalization for RSV-related LRTI. Any ambiguous cases were reviewed on a case-by-case basis.

The follow-up period began on the immunization date for immunized infants and on November 1<sup>st</sup>, 2023, for non-immunized infants in the catch-up group. For non-immunized infants in the seasonal group, the follow-up period began on the date of birth. For nirsevimab recipients, the follow-up lasted for 150 days from the date of immunization, outcome (hospitalization) or death, whichever occurred first. For nirsevimab non-recipients, the follow-up lasted until the occurrence of an outcome (hospitalization), death or the end of the campaign on 31 March 2024, whichever occurred first.

A case of hospitalization for RSV-related LRTI was defined as a child under two years of age with an LRTI who was admitted to the hospital and had a nasopharyngeal swab that tested positive for RSV by RT-PCR.

Severe RSV-related LRTI was defined as requiring respiratory support (supplemental oxygen therapy, high-flow nasal cannula [HFNC] oxygen therapy, non-invasive mechanical ventilation, and invasive mechanical ventilation) and/or admission to an intensive care unit (ICU).

All children hospitalized due to an acute respiratory illness during RSV season were routinely tested for RSV. Nasopharyngeal exudate samples were collected using sterile swabs with viral transport medium. These samples were analyzed in the hospital laboratory using RT-PCR.

### Data collection

Data on RSV-related LRTI hospitalizations during the RSV seasons between 2017-18 and 2023-24 were collected from SEIS-RAM (the electronic health information system used in Madeira that includes centralized hospital and primary care clinical records for each patient). RSV seasons during the COVID-19 pandemic (2020-21, 2021-22) were excluded due to potential changes in RSV circulation.

Sociodemographic characteristics, immunization status, laboratory test results and clinical records were systematically collected through this information system. All data were retrospectively gathered after the follow-up period ended.

### Statistical analysis

To assess statistical differences in demographic characteristics between immunized and non-immunized infants, as well as statistical differences in clinical outcomes between 2023-24 RSV season and previous seasons (2017-18, 2018-19, 2019-20, 2022-23), we used a Student's t-test or a Mann-Whitney test for continuous variables, and a Chi-squared test for categorical variables. The clinical endpoints evaluated were RSV-related LRTI hospitalization, severe RSV-related LRTI requiring respiratory support (supplemental oxygen therapy, HFNC oxygen therapy, non-invasive ventilation, invasive ventilation) and severe RSV-related LRTI requiring ICU admission.

To estimate the effectiveness of nirsevimab, we used a Cox proportional hazards regression model adjusted for age and sex. Calculated hazard ratios (HR) were presented with a 95% confidence interval (CI). The effectiveness of nirsevimab against RSV-related hospitalization was estimated as  $(1 - \text{adjusted HR}) \times 100$ . A Kaplan-Meier survival analysis was conducted to estimate the mean time without hospitalization in the

immunized and non-immunized groups. The number needed to immunize (NNI) to avoid one RSV-related LRTI hospitalization was calculated as the inverse of the absolute risk reduction.

To estimate the number of averted cases and relative reduction (%) compared to previous seasons, we calculated the ratio of infants hospitalized in their first RSV season to those in their second RSV season in previous seasons. Based on these ratios, we estimated the expected number of RSV-related hospitalizations among infants in their first RSV season if no immunoprophylaxis was given by using the observed number of infants who were hospitalized for RSV-related LRTI in their second RSV season in 2023-24. We then subtracted the observed number of RSV-related LRTI hospitalizations from the estimated number to determine the number of averted cases. The relative reduction was represented by the number of averted cases, divided by the expected number of cases and expressed as a percentage.

Analyses were performed using SPSS software (version 25.0, SPSS Inc.). A *P* value of less than 0.05 was considered statistically significant.


## Results

### Immunization campaign for the 2023-24 RSV season

Between April 1<sup>st</sup>, 2023, and March 31<sup>st</sup>, 2024, 1,986 infants were born, of whom 230 were excluded. Two newborns were admitted to the ICU at birth and subsequently died for clinical reasons unrelated to RSV infection. Additionally, 228 infants were not residing in Madeira. Out of the 1,756 infants eligible for nirsevimab administration, 745 (42.4%) were in the seasonal group and 1,011 (57.6%) were in the catch-up group (Fig. 1).

The overall immunization rate was 97.4% (1,710/1,756 eligible), with similar coverage in the seasonal and catch-up groups (97.7% and 97.1%, respectively) (Fig. 2). Infants in the catch-up group were immunized at their primary care office, with priority given to younger infants. Within the first month of the immunization campaign, the immunization rate in the catch-up group was 92.3% (Fig. 2; B).

The median age at immunization was one month (IQR 0-4). The median gestational age at birth was 39 weeks (IQR 38-40). Out of the 1,756 infants, 104 (6%) were born preterm, 102 (98.1%) of whom were immunized with nirsevimab.



**Figure 2.** Nirsevimab immunization coverage (%) during the 2023-24 RSV season. **A:** all immunized eligible infants; **B:** immunized infants in the catch-up group; **C:** immunized infants in the seasonal group.

Disparity in the sizes of the two groups was noted. The descriptive characteristics of infants eligible for immunization with nirsevimab are shown in Table 1.

No adverse effects were reported through the pharmacovigilance system notification platform.

#### **Effectiveness of nirsevimab in RSV-related LRTI hospitalizations in the 2023-24 season**

During the follow-up period, 16 RSV-related LRTI hospitalizations were registered, eight of which were eligible for immunization with nirsevimab (Table 2). Of these, six were nirsevimab recipients and two were considered non-recipients: one infant due to parental refusal, and another who began showing respiratory symptoms two days prior to being immunized and was admitted to the hospital two days after the immunization.

The mean time without hospitalization was longer in the immunized group (149.6 days; 95% CI 149.3-149.9)

than in the non-immunized group (145.1 days; 95% CI 137.0-153.1), with statistical significance ( $P < .001$ ).

Among immunized infants who required hospitalization, the median number of days between immunization and the onset of respiratory symptoms was 37 days (IQR 19.8-52.0).

The estimated effectiveness of nirsevimab against hospitalization for RSV-related LRTI was 94.6% (95% CI 72.6-98.9), while it was 91.7% (95% CI 23.7-99.1) against that for severe RSV-related LRTI with supplemental oxygen therapy. Due to the limited number of hospitalizations, nirsevimab effectiveness against severe RSV-related LRTI requiring ICU admission, HFNC oxygen therapy, non-invasive ventilation and invasive mechanical ventilation could not be determined (Table 2).

Nirsevimab non-recipients were 13 times more likely to be hospitalized (OR 12.91 [95% CI 2.53-65.76];  $P < 0.0001$ ) than nirsevimab recipients. The NNI was 25.

**Table 1.** Demographic and clinical characteristics of infants eligible for immunization with nirsevimab

|                                            | Total<br>(n = 1,756) | Immunization with nirsevimab |                     | P      |
|--------------------------------------------|----------------------|------------------------------|---------------------|--------|
|                                            |                      | Yes<br>(n = 1,710)           | No<br>(n = 46)      |        |
| Immunization group, No. (%)                |                      |                              |                     |        |
| Catch-up                                   | 1,011 (57.6)         | 982 (57.4)                   | 29 (63.0)           | 0.447* |
| Seasonal                                   | 745 (42.4)           | 728 (42.6)                   | 17 (37.0)           |        |
| Age, months                                |                      |                              |                     |        |
| Mean (SD)                                  | 1.9 (2.3)            | 1.9 (2.3)                    | 2.4 (2.3)           | 0.199† |
| Median (IQR)                               | 1 (0-4)              | 1 (0-4)                      | 2 (0-4)             | 0.133‡ |
| Sex, No. (%)                               |                      |                              |                     |        |
| Female                                     | 836 (47.6)           | 819 (47.9)                   | 17 (37.0)           | 0.143* |
| Male                                       | 920 (52.4)           | 891 (52.1)                   | 29 (63.0)           |        |
| Gestational age at birth, weeks            |                      |                              |                     |        |
| Mean (SD)                                  | 39 (1.8)             | 39 (1.8)                     | 39.1 (1.3)          | 0.673† |
| Median (IQR)                               | 39 (38-40)           | 39 (38-40)                   | 39 (39-40)          | 0.826‡ |
| Preterm birth, No. (%)                     |                      |                              |                     |        |
| No, ≥ 37 weeks                             | 1,621 (94.0)         | 1,578 (93.9)                 | 43 (95.6)           | 0.651* |
| Yes, < 37 weeks                            | 104 (6.0)            | 102 (6.1)                    | 2 (4.4)             |        |
| Weight at birth, grams                     |                      |                              |                     |        |
| Mean (SD)                                  | 3,208 (497)          | 3,206 (497)                  | 3,299 (506)         | 0.222† |
| Median (IQR)                               | 3,240 (2,945-3,505)  | 3,240 (2,945-3,500)          | 3,295 (2,910-3,595) | 0.266‡ |
| Risk factors for severe infection, No. (%) | 11 (0.6)             | 11 (0.6)                     | 0                   | -      |

\*Chi-squared test.

<sup>†</sup>Student's t-test.<sup>‡</sup>Mann-Whitney test.Statistical significance for  $P < .05$ .**Table 2.** Nirsevimab effectiveness against hospitalizations for RSV-related LRTI in the 2023-24 RSV season

|                                                              | Nirsevimab non-recipients |       | Nirsevimab recipients |       | Crude HR<br>(95% CI)*  | Effectiveness, %<br>(95% CI)* | Adjusted HR<br>(95% CI) <sup>†</sup> | Effectiveness, %<br>(95% CI) <sup>†</sup> |
|--------------------------------------------------------------|---------------------------|-------|-----------------------|-------|------------------------|-------------------------------|--------------------------------------|-------------------------------------------|
|                                                              | Events                    | Total | Events                | Total |                        |                               |                                      |                                           |
| Hospitalization for RSV-related LRTI                         | 2                         | 46    | 6                     | 1,710 | 0.072<br>(0.014-0.356) | 92.8 (64.4-98.6)              | 0.054<br>(0.011-0.274)               | 94.6 (72.6-98.9)                          |
| Severe RSV-related LRTI with supplemental oxygen therapy     | 1                         | 46    | 4                     | 1,710 | 0.096<br>(0.011-0.859) | 90.4 (14.1-98.9)              | 0.083<br>(0.009-0.763)               | 91.7 (23.7-99.1)                          |
| Severe RSV-related LRTI with ICU admission                   | 0                         | 46    | 2                     | 1,710 | NA                     | NA                            | NA                                   | NA                                        |
| Severe RSV-related LRTI with HFNC oxygen therapy             | 0                         | 46    | 2                     | 1,710 | NA                     | NA                            | NA                                   | NA                                        |
| Severe RSV-related LRTI with non-invasive ventilation        | 0                         | 46    | 1                     | 1,710 | NA                     | NA                            | NA                                   | NA                                        |
| Severe RSV-related LRTI with invasive mechanical ventilation | 0                         | 46    | 1                     | 1,710 | NA                     | NA                            | NA                                   | NA                                        |

\*Not adjusted.

<sup>†</sup>Adjusted for age and sex.

CI: confidence interval; HFNC: high-flow nasal cannula; HR: hazard ratio; ICU: intensive care unit; LRTI: lower respiratory tract infection; NA: not applicable; RSV: respiratory syncytial virus.

**Table 3.** Comparison between hospitalizations for RSV-related LRTI in RSV season 2023-24 and previous seasons (2017-18, 2018-19, 2019-20, 2022-23)

|                                                                | Previous RSV seasons<br>(n = 103) | RSV season 2023-24<br>(n = 16) | P value            |
|----------------------------------------------------------------|-----------------------------------|--------------------------------|--------------------|
| Hospitalization for RSV-related LRTI                           |                                   |                                |                    |
| Duration, median (min-max), days                               | 5 (1-19)                          | 3.5 (1-13)                     | 0.072 <sup>†</sup> |
| Severe RSV-related LRTI requiring respiratory support, No. (%) | 84 (81.6)                         | 10 (62.5)                      | 0.101*             |
| Duration, median (min-max), days                               | 2 (0-8)                           | 1 (0-15)                       | 0.068 <sup>†</sup> |
| Supplemental oxygen therapy, No. (%)                           | 84 (81.6)                         | 10 (62.5)                      | 0.101*             |
| Duration, median (min-max), days                               | 3 (0-8)                           | 1 (1-8)                        | 0.039 <sup>†</sup> |
| High-flow nasal cannula oxygen therapy, No. (%)                | 3 (2.9)                           | 2 (12.5)                       | 0.133*             |
| Duration, median (min-max), days                               | 2 (2-3)                           | 1 (1-1)                        | 0.068 <sup>†</sup> |
| Non-invasive ventilation, No. (%)                              | 3 (2.9)                           | 1 (6.3)                        | 0.443*             |
| Duration, median (min-max), days                               | 2 (2-2)                           | 8 (8-8)                        | 0.083 <sup>†</sup> |
| Invasive ventilation, No. (%)                                  | 0 (0.0)                           | 1 (6.3)                        | 0.134*             |
| Duration, median (min-max), days                               | -                                 | 5 (5-5)                        | -                  |
| Severe RSV-related LRTI requiring ICU admission, No. (%)       | 10 (9.7)                          | 2 (12.5)                       | 0.664*             |

\*Chi-squared test.

<sup>†</sup>Mann-Whitney test. Statistical significance for  $P < .05$ .

RSV: respiratory syncytial virus; LRTI: lower respiratory tract infection; ICU: intensive care unit.

### RSV season 2023-24 and previous seasons (2017-18, 2018-19, 2019-20, 2022-23)

Comparing the 2023-24 season with previous seasons (2017-18, 2018-19, 2019-20, 2022-23), the median duration, in days, of supplemental oxygen therapy was significantly lower ( $P = .039$ ). There were no significant differences in the other assessed outcomes (Table 3).

In the 2023-24 season, the two infants who required admission to the ICU had been immunized with nirsevimab. One was a 26-week premature infant who required supplemental oxygen therapy, HFNC oxygen therapy, non-invasive ventilation and invasive ventilation. The other infant was born at term and required 24 hours of supplemental oxygen therapy and 24 hours of HFNC oxygen therapy. It is worth noting that HFNC oxygen therapy is currently only available in the ICU at our institution.

Based on previous seasons (2017-18, 2018-19, 2019-20, 2022-23), the estimated median number of averted cases was 45 (IQR 15-83) and that of relative reduction in hospitalizations was 79.6% (IQR 62.6-90.9) (Table 4).

## Discussion

Nirsevimab was 94.6% (95% CI 72.6-98.9) effective in preventing RSV-related LRTI hospitalizations, adjusted for age and sex. The median duration of

supplemental oxygen therapy was significantly shorter in the 2023-24 RSV season than in previous seasons ( $P = .039$ ). The NNI was 25. A median relative reduction of 79.6% (IQR 62.6-90.9) in hospitalizations was noted, with a median of 45 averted cases (IQR 15-83). No adverse effects have been reported by the publication date of this paper.

Randomized clinical trials such as MELODY<sup>10</sup> and HARMONIE<sup>9</sup> have reported efficacy rates of 62.1% and 83.2%, respectively, against RSV-related LRTI hospitalizations. Our analysis demonstrated that nirsevimab was 94.6% (95% CI 72.6-98.9) effective in preventing hospitalizations for RSV-related LRTI. This is consistent with the results of other real-world studies conducted in France (83%; 95% CI 73.4-89.2)<sup>16</sup>, in the USA (90%; 95% CI 75-96)<sup>17</sup> and in several regions of Spain, namely in Navarre (88.7%; 95% CI 69.6-95.8)<sup>18</sup>, Catalonia (87.6%; 95% CI 82.1-91.4)<sup>19</sup>, Galicia (82%; 95% CI 65.6-90.2)<sup>20</sup>, and across Valencia, Murcia and Valladolid (84.4%; 95% CI 76.8-90)<sup>21</sup>. In our study, the estimated effectiveness of nirsevimab estimated effectiveness against severe RSV-related LRTI requiring supplemental oxygen therapy was 91.7% (95% CI 23.7-99.1), similar to that reported in Galicia<sup>20</sup> (86.9%; 95% CI 69.1-94.2).

Based on previous RSV seasons, the median number of averted cases was 45 (IQR 15-83), corresponding to a median relative reduction of hospitalizations of

**Table 4.** Impact of nirsevimab in hospitalizations for RSV-related LRTI in RSV season 2023-24 based on previous seasons (2017-18, 2018-19, 2019-20, 2022-23)

|                                                         | RSV season |         |         |         | Median (IQR)     |
|---------------------------------------------------------|------------|---------|---------|---------|------------------|
|                                                         | 2017-18    | 2018-19 | 2019-20 | 2022-23 |                  |
| RSV-related LRTI hospitalization ratio (1st:2nd season) | 10.0       | 15.5    | 3.3     | 1.8     |                  |
| Estimates for the 2023-24 season                        |            |         |         |         |                  |
| Expected number of hospitalizations (1st season) *      | 80         | 124     | 26      | 14      | 53 (23-91)       |
| Averted number of cases <sup>†</sup>                    | 72         | 116     | 18      | 6       | 45 (15-83)       |
| Relative reduction (%)                                  | 90.0       | 93.5    | 69.2    | 43.8    | 79.6 (62.9-90.9) |

\*To estimate the expected number of RSV-related hospitalizations among infants in their first RSV season if no immunoprophylaxis was administered, we multiplied the number of infants who passed their second RSV season in 2023-24 (8 infants) by the ratio (1<sup>st</sup>:2<sup>nd</sup> season) in previous seasons.

<sup>†</sup>The averted number of cases was calculated by subtracting number of infants hospitalized for RSV-related LRTI who were passing their first RSV season in 2023-24 (8 infants) from the expected number of cases.

RSV: respiratory syncytial virus; LRTI: lower respiratory tract infection.

79.6% (IQR 62.6-90.9), which is consistent with the 69% reduction in cases among infants under six months of age in Luxembourg from 2022 to 2023<sup>22</sup>, the estimated 89.84% reduction (IQR 87.58-90.30) reported in Galicia<sup>20</sup>, and 47.6% reduction in Navarre<sup>18</sup>.

The NNI is essential for determining the potential public health impact of an immunization program, depending on the observed effectiveness. According to Finelli et al.<sup>23</sup>, who modelled the anticipated public health benefits of RSV immunization with an extended-life monoclonal antibody, and estimated that 37-280 infants would need to be immunized to prevent one RSV-associated hospitalization in the first year of life, assuming 70% efficacy. The authors acknowledge the possibility of underestimating incidence rates, which could lead to higher NNI values. Additionally, as efficacy increases, the NNI decreases. Therefore, given that the real-world effectiveness is estimated to be higher than the chosen mid-reference point of 70%, and acknowledging the potential overestimation of the NNI, we consider our NNI of 25 to be consistent with this model, making it a suitable strategy. Moreover, our NNI aligns with the results of other real-world studies conducted in Galicia (median 25; IQR 24-32)<sup>20</sup> and Navarre (15.3)<sup>18</sup>.

The nirsevimab immunization campaign was well received by our regional community, achieving an overall immunization rate of 97.4%, with similar rates in the seasonal and catch-up groups. This can be partly explained by the methodical immunization campaign, which provided comprehensive information and educational content for both the community and healthcare professionals. This campaign was promoted across diverse social media platforms, online, and in print. The immunization rate in the catch-up group in the

campaign's first month was 92.3%, in comparison to Catalonia (76.3%)<sup>19</sup> and Murcia (90% in 39 days)<sup>24</sup>. Within this timeframe, this outstanding immunization rate is primarily the result of the well-coordinated and efficient logistics handled by the primary care centers. Furthermore, immunizing infants in maternity wards reduced the number of infants scheduled at primary care centers. This eliminated the need for additional immunization sites and reduced the likelihood of unadministered immunizations due to appointments being missed. The absence of reported adverse effects supports the safety of this immunoprophylaxis in this age group<sup>9,10,12,14,18</sup>.

This study has some limitations. Firstly, the limited number of events, likely resulting from the small analyzed population size, made it impossible to estimate the effectiveness of nirsevimab effectiveness against various endpoints. Secondly, due to the implementation of VigiRSV during the 2021-22 RSV season, RT-PCR testing for RSV was only routinely conducted in all patients hospitalized for LRTI from that point onward. In previous seasons, RSV testing was performed at the discretion of individual clinicians, meaning the total number of cases during those seasons is presumably an underestimation of the actual number of RSV-related LRTI hospitalizations.

This study has several strengths, including the inclusion of only RT-PCR-confirmed RSV-positive cases, data sourced from an integrated electronic health information system encompassing both hospital and primary care clinical records, and the use of historical data from seasons prior to the COVID-19 pandemic. The latter allowed us to account for changes in RSV circulation following the pandemic, rather than relying solely on data from the 2022-23 RSV season for

comparisons. Furthermore, as the first national study to assess the real-world outcomes of nirsevimab immunization in its inaugural season, our findings offer valuable insights for shaping prophylactic strategies against RSV infection and strengthening community adherence in the future.

## Conclusion

Nirsevimab has proved to be highly effective in reducing hospitalizations for RSV-related LRTI in real-world settings. Madeira was a pioneer in recommending universal immunoprophylaxis with nirsevimab against RSV infection for all infants during their first RSV season in Portugal. Our study is the first nationwide one, and one of the few worldwide, to shed light on the effectiveness of nirsevimab beyond clinical trials. These results offer pivotal evidence to inform RSV immunization strategies and public health policies. Further studies are needed to assess the effectiveness of nirsevimab in other clinical settings, such as emergency departments and primary care settings, and to perform a cost-effectiveness analysis.

## Acknowledgements

The authors would like to thank Dr Lucília Aveiro for her collaboration and support throughout this study, and all those who contributed to data collection.

## Author contributions

A. Afonso, F. Pestana: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – Original Draft, Writing – Review & Editing.

M. Rodrigues: Data curation, Formal analysis, Methodology, Software, Visualization, Writing – Review & Editing.

A. Andrade, B. Camacho: Conceptualization, Methodology, Supervision, Writing – Review & Editing.

J. Alves: Conceptualization, Data curation, Methodology, Resources, Writing – Review & Editing.

T. Jacinto, E. Costa, B. R. Gouveia: Conceptualization, Writing – Review & Editing.

C. Freitas: Conceptualization, Methodology, Project administration, Supervision, Writing – Review & Editing.

All authors approved the final version to be published.

## Financing sources

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

## Awards and previous presentations

Preliminary data from this study were presented as an oral presentation at the “24<sup>º</sup> Congresso Nacional de Pediatria”, where it was awarded the “Grande Prémio SPP”.

## Conflicts of interest

None.

## Ethical disclosures

**Protection of humans and animals.** The authors declare that no experiments involving humans or animals were conducted for this research.

**Confidentiality, informed consent, and ethical approval.** The authors have obtained approval from the Ethics Committee for the analysis of routinely obtained and anonymized clinical data, so informed consent was not necessary. Relevant guidelines were followed.

**Declaration on the use of artificial intelligence.** The authors declare that no generative artificial intelligence was used in the writing of this manuscript.

## References

- Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet*. 2022;399(10340):2047-2064.
- Bandeira T, Carmo M, Lopes H, Gomes C, Martins M, Guzman C, et al. Burden and severity of children's hospitalizations by respiratory syncytial virus in Portugal, 2015-2018. *Influenza Other Respi Viruses*. 2023;17(1):e13066.
- Curns AT, Rha B, Lively JY, Sahni LC, Englund JA, Weinberg GA, et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Children <5 Years Old: 2016 to 2020. *Pediatrics*. 2024;153(3).
- Wildenbeest JG, Billard M-N, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. *Lancet Respir Med*. 2023;11(4):341-353.
- Direção Regional de Estatística da Madeira. População e Condições Sociais: Demografia. 2023. Accessed August 1, 2024. <https://app.powerbi.com/view?r=eyJrIjoibmMOMzUxM2EtNDNmNC00ODcwLThtMzktNDUzNTg3Y2Y2Nm0lIiwidCI6IjcxOTQwYTg2LTUyYmQtNGVhMm00OWI3LWUwYTdjZDcwNDAMyIsImMiOjIj>
- Serviço de Saúde da Região Autónoma da Madeira. *Dados Da Rede de Vigilância VigiRSV - RAM*. Dados não publicados; 2023.
- European Medicines Agency (EMA). Beyfortus (nirsevimab) - An overview of Beyfortus and why it is authorised in the EU. Published online 2022. Accessed July 30, 2024. [https://www.ema.europa.eu/en/documents/overview/beyfortus-epar-medicine-overview\\_en.pdf](https://www.ema.europa.eu/en/documents/overview/beyfortus-epar-medicine-overview_en.pdf)
- Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. *Sci Transl Med*. 2017;9(388).
- Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. *N Engl J Med*. 2023;389(26):2425-2435.
- Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. *N Engl J Med*. 2022;386(9):837-846.
- Muller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, et al. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. *N Engl J Med*. 2023;388(16):1533-1534.
- Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. *N Engl J Med*. 2020;383(5):415-425.

13. Direção Regional de Saúde da Região Autónoma da Madeira. *Circular Normativa 2023/1797: Imunoprofilaxia Com Nirsevimab Para a Prevenção Da Infecção Pelo Vírus Sincicial Respiratório Em Crianças - Época 2023-2024.*; 2023. Accessed August 22, 2024. [https://www.madeira.gov.pt/Portals/53/Documentos/GASA/circular\\_normativa\\_1797\\_2023\\_infecao\\_virus\\_sincicial\\_respiratorio\\_crianças.pdf](https://www.madeira.gov.pt/Portals/53/Documentos/GASA/circular_normativa_1797_2023_infecao_virus_sincicial_respiratorio_crianças.pdf)
14. Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, et al. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. *N Engl J Med.* 2022;386(9):892-894.
15. Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sánchez PJ, et al. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(34):920-925.
16. Assad Z, Romain A-S, Aupiais C, Shum M, Schrimpf C, Lorrot M, et al. Nirsevimab and hospitalization for RSV bronchiolitis. *N Engl J Med.* 2024;391(2):144-154.
17. Moline HL, Tannis A, Toepler AP, Williams JV, Boom JA, Englund JA, et al. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. *MMWR Morb Mortal Wkly Rep.* 2024;73(9):209-214.
18. Ezpeleta G, Navascués A, Viguria N, Herranz-Aguirre M, Juan Belloc SE, Gimeno Ballester J, et al. Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study. *Vaccines (Basel).* 2024;12(4).
19. Coma E, Martínez-Marcos M, Hermosilla E, Mendioroz J, Reñé A, Fina F, et al. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain). *Arch Dis Child.* 2024;109(9):736-741.
20. Ares-Gómez S, Mallah N, Santiago-Pérez M-I, Pardo-Seco J, Pérez-Martínez O, Otero-Barrós M-T, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. *Lancet Infect Dis.* 2024;24(8):817-828.
21. López-Lacort M, Muñoz-Quiles C, Mira-Iglesias A, López-Labrador FX, Mengual-Chuliá B, Fernández-García C, et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. *Euro Surveill.* 2024;29(6).
22. Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C, et al. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalizations during the initial 2023/24 season in Luxembourg. *Euro Surveill.* 2024;29(4).
23. Finelli L, Choi Y, Goldstein E. Number needed to immunize to prevent RSV with extended half-life monoclonal antibody. *Vaccine.* 2020;38(34):5474-5479.
24. Pérez Martín JJ, Zomoza Moreno M. Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain. *Hum Vaccin Immunother.* 2024;20(1):2365804.